NIVELLES, Belgium & BEGLES, France – August 24, 2026 – Quantoom Biosciences and Inside Therapeutics today announced a commercial collaboration designed to give RNA researchers and developers a simpler, more integrated path from RNA production to lipid nanoparticle (LNP) formulation. By connecting their complementary benchtop technologies, the two companies aim to reduce friction across the early-stage mRNA and saRNA development workflow.
Through this collaboration, the companies will create a seamless bridge for customers across their respective platforms. Quantoom Biosciences brings its Ntensify Micro and Ntensify Mini benchtop systems for RNA production, while Inside Therapeutics contributes its TAMARA platform for LNP formulation. Together, these solutions cover consecutive steps of the RNA drug-product workflow, allowing customers to source proven, complementary equipment through a coordinated commercial relationship.
“Partnering with Inside Therapeutics lets us offer researchers a smoother journey from RNA synthesis to formulation,” said José Castillo, CEO of Quantoom Biosciences. “Our Ntensify® benchtop systems and Inside Therapeutics’ TAMARA platform are a natural fit, and this collaboration makes it easier for customers to access both.”
“We are excited to collaborate with Quantoom Biosciences to connect RNA production and LNP formulation under one coordinated offering,” said Robin OLIVERES, CBO of Inside Therapeutics. “By bringing our platforms together, we help our customers move faster from concept to formulated product.”
The collaboration is non-exclusive and focuses on joint customer referrals, coordinated marketing, and a shared presence at key industry events. Both companies will continue to operate and sell independently while working to deliver a more connected experience for the global RNA research community.
About Quantoom Biosciences
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. Quantoom Biosciences is a trade name of Phoenix Biosciences SA. For more information about Quantoom Biosciences, visit www.quantoom.com
About Inside Therapeutics
Inside Therapeutics (InsideTx) is a Bordeaux-based deep-tech streamlining RNA-LNP formulation, from screening to manufacturing. Its formulation technologies span low-volume, zero-loss R&D platforms through to a patented scale-up approach designed to keep nanoparticle characteristics identical from bench to production.
Contacts
Quantoom Biosciences — Thomas GUYON, Product Marketing (t.guyon@quantoom.com)
Inside Therapeutics – — Thomas GUERINIER, CEO Inside Therapeutics (thomas.guerinier@insidetx.com)
